Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition - sprookjes - yvandenbroek - TriplyDB

Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition

Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition

http://www.wikidata.org/entity/Q33880093

about

Correlation between Trop2 and amphiregulin coexpression and overall survival in gastric cancer Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma MiR-34a suppresses amphiregulin and tumor metastatic potential of head and neck squamous cell carcinoma (HNSCC)Abnormal amphiregulin expression correlates with gastric cancer prognosis.Drugging PI3K in cancer: refining targets and therapeutic strategies Expanding primary cells from mucoepidermoid and other salivary gland neoplasms for genetic and chemosensitivity testing.

P2860

Q33679575-F9685919-D3EA-4FD1-A108-76EECF1B4CA9 Q34957243-6701BD8C-01CD-40C6-9A0F-DF870BED7BAA Q35238420-4592A8DC-960B-493E-A296-2A9C58E847BB Q35781321-84B114D9-C9D7-41CB-9C92-651A1F32C2EC Q37718266-4968DD16-F36E-47D5-9337-88B3CDA0EDD8 Q38539217-8D6CC437-487D-4187-A991-E02A9F99C0D2 Q50119043-FDF59D0D-D850-4FF3-984F-F6520603E2AA

P2860

Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition

http://www.wikidata.org/entity/Q33880093

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Amphiregulin and PTEN evoke a ...... resistance to PI3K inhibition

@ast

Amphiregulin and PTEN evoke a ...... resistance to PI3K inhibition

@en

type

label

Amphiregulin and PTEN evoke a ...... resistance to PI3K inhibition

@ast

Amphiregulin and PTEN evoke a ...... resistance to PI3K inhibition

@en

prefLabel

Amphiregulin and PTEN evoke a ...... resistance to PI3K inhibition

@ast

Amphiregulin and PTEN evoke a ...... resistance to PI3K inhibition

@en

P1433

Q33880093-933BDADA-CAB4-451A-BAA7-3FAA62231A89

P1476

Q33880093-C4728022-EC78-40B3-A9AF-2F4EC38FC602

P2093

Q33880093-10393F03-5361-4816-AB8A-ACD42791D119

Q33880093-20C44AB8-2A4E-4A6B-AD9A-73D6D08D835A

Q33880093-58CA06D0-565B-4DCA-A5CC-246E55A575EF

Q33880093-9B720573-9367-43FA-A26C-FCFFB9F89C74

Q33880093-AA63796F-52F0-4652-AAE2-95D41D6685D7

Q33880093-B18A65F5-CD53-41FE-AF6E-E3C5A811888A

Q33880093-B86D79DE-AFF9-4AC2-B7ED-2FEF6B4C8D85

Q33880093-BAAFA816-F827-46FD-B604-00746D21F417

Q33880093-BC051E9B-2518-4551-B496-AEDFAEA323FC

Q33880093-CCCEB7E3-6BED-4855-BEDB-8115D7F28275

P2860

Q33880093-409AD908-553B-44FC-BA03-581F06380057

Q33880093-4873C41B-7757-4528-A33C-075955D6440E

Q33880093-48D8FDC6-B668-4A03-A032-682A286F0C0C

Q33880093-48DE7BC8-BFBD-4027-BC7C-DDB45092ACB2

Q33880093-501C2F12-9DDE-444E-B0E4-E5258EA1C1B7

Q33880093-52BAD533-2D5E-40DC-ACA8-2EDEB196D415

Q33880093-57F35228-E120-4BCF-844F-212484112495

Q33880093-5A3A2684-7542-4822-961D-1F1143EF64EC

Q33880093-5D58A419-4E22-4205-A471-C3B3086CFCD6

Q33880093-63BD7DE7-EE60-438A-9DBE-F933AA0C91DA

P304

Q33880093-9C4C7BC8-47E9-4DB9-A6B8-2F7EF63D0E66

P31

Q33880093-27117704-3A0B-469F-952E-A5A2382AE9F3

P356

Q33880093-E469BCBC-9456-4BBC-9BE1-5972868BF336

P433

Q33880093-A772BB1E-6AF6-4428-BE20-D3676820DBE4

P478

Q33880093-F1C27EC9-AD77-4EF4-9B48-A59EE2E3629F

P50

Q33880093-38F78495-FD53-44B9-B3E7-258CBE61029A

P577

Q33880093-5266DF2D-C77E-4279-A7B6-AA6982540FAA

P698

Q33880093-43549655-66B4-4FFA-A259-775836F3F6A9

P932

Q33880093-F18453F4-1011-4CA1-A3B9-4FCC545D2816

P356

GENESANDCANCER.10

P1433

P1476

Amphiregulin and PTEN evoke a ...... resistance to PI3K inhibition

@en

P2093

Deepak Sampath

http://www.w3.org/2001/XMLSchema#string

Eric Cheng

http://www.w3.org/2001/XMLSchema#string

Jeffrey J Wallin

http://www.w3.org/2001/XMLSchema#string

Kyle A Edgar

http://www.w3.org/2001/XMLSchema#string

Lisa Crocker

http://www.w3.org/2001/XMLSchema#string

Lori S Friedman

http://www.w3.org/2001/XMLSchema#string

Marcia Belvin

http://www.w3.org/2001/XMLSchema#string

Marie-Claire Wagle

http://www.w3.org/2001/XMLSchema#string

Nicholas Dompe

http://www.w3.org/2001/XMLSchema#string

Richard M Neve

http://www.w3.org/2001/XMLSchema#string

P2860

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

High frequency of mutations of the PIK3CA gene in human cancers

PI3K pathway alterations in cancer: variations on a theme

p120cbl is a cytosolic adapter protein that associates with phosphoinositide 3-kinase in response to epidermal growth factor in PC12 and other cells.

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

EGF receptor ligands.

Epidermal growth factor receptor: mechanisms of activation and signalling.

P304

113-126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/GENESANDCANCER.10

http://www.w3.org/2001/XMLSchema#string

P433

3-4

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Matthew J Wongchenko

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25053989

http://www.w3.org/2001/XMLSchema#string

P932

4091530

http://www.w3.org/2001/XMLSchema#string